Request Demo
Last update 07 Nov 2026
Nilvanstomig
Last update 07 Nov 2026
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms ZG-005, ZG005 |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 453608435
Source: *****
Sequence Code 453608436
Source: *****
Related
17
Clinical Trials associated with NilvanstomigNCT07833839
A Randomized, Double-Blind, Controlled, Multicenter Phase III Clinical Trial of ZG005 in Combination With Etoposide and Cisplatin Versus Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma
NCT07813572
A Phase 3, Randomized, Open-Label, Active-Controlled, Multicenter Study of ZG005 in Combination With Bevacizumab Versus Sintilimab in Combination With Bevacizumab in the First-Line Treatment of Advanced Hepatocellular Carcinoma
NCT07099547
A Study to Evaluate the Efficacy and Safety of ZG005 in Combination With Platinum-Based Chemotherapy as First-Line Treatment in Participants With Advanced Biliary Tract Carcinoma
100 Clinical Results associated with Nilvanstomig
Login to view more data
100 Translational Medicine associated with Nilvanstomig
Login to view more data
100 Patents (Medical) associated with Nilvanstomig
Login to view more data
100 Deals associated with Nilvanstomig
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Neuroendocrine Carcinoma | Phase 3 | China | 28 Sep 2026 | |
| Advanced Hepatocellular Carcinoma | Phase 3 | China | 01 Sep 2026 | |
| Biliary Tract Neoplasms | Phase 2 | China | 02 Dec 2025 | |
| Advanced biliary tract cancer | Phase 2 | China | 11 Nov 2025 | |
| Gallbladder adenocarcinoma | Phase 2 | China | 11 Nov 2025 | |
| Gallbladder Neoplasms | Phase 2 | China | 11 Nov 2025 | |
| Metastatic gallbladder cancer | Phase 2 | China | 11 Nov 2025 | |
| Small Cell Lung Cancer | Phase 2 | China | 23 Sep 2025 | |
| Advanced Lung Small Cell Carcinoma | Phase 2 | China | 04 Sep 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 29 May 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1/2 | 55 | lmydkkvwgv(grzjxnaeaz) = bsttfzkckq iwxaqkfdxx (peoewcfcvh ) View more | Positive | 23 Oct 2026 | |||
Phase 1/2 | Advanced Cervical Carcinoma First line | 96 | grpyoyglkm(eaqjyidxso) = rqlvfnlxqt vmbgktflhe (eztkupqaye ) View more | Positive | 23 Oct 2026 | ||
dqtfamyfvc(dgejobemit) = qqwhcivbci vjgdvknsjj (izcxecbxen ) | |||||||
Phase 1/2 | Advanced Neuroendocrine Carcinoma First line | 57 | audhxlnpjy(tzsjwitpnm) = yvrydbdtpp apdgzfedlr (icylyojftb ) View more | Positive | 23 Oct 2026 | ||
audhxlnpjy(tzsjwitpnm) = mufimxtuat apdgzfedlr (icylyojftb ) View more | |||||||
Phase 2 | Advanced Hepatocellular Carcinoma First line | 95 | lfbavbpaey(zekzyhtxxw) = vafyogkzdx gqfjudesnh (gpzawiffob ) View more | Positive | 29 May 2026 | ||
lfbavbpaey(zekzyhtxxw) = ynzsfbjxsn gqfjudesnh (gpzawiffob ) View more | |||||||
Phase 1 | 21 | cakxuvdzwo(ggywbrckqd) = jarjnjyarj qpcdloejtf (ibkbjsrlgc ) View more | Positive | 31 Oct 2025 | |||
| - | Advanced Cervical Carcinoma First line | 60 | bcxnkwqtjp(jmzkbfqcqq) = uwdwllsioi irbruzhagu (biygzmrmbk ) View more | Positive | 31 Oct 2025 | ||
ocnmpnffoq(ggrokgtbyz) = ckekyapskl laqdhgniwe (mbptzuxdbw ) View more | |||||||
Phase 1/2 | Advanced Neuroendocrine Carcinoma First line | 39 | xxkvuiwtrn(qpiioklafh) = No dose-limiting toxicities (DLT) were observed in part 1 juhlmirhpp (rljmeybrnb ) View more | Positive | 17 Oct 2025 | ||
Phase 1/2 | Advanced Neuroendocrine Carcinoma First line | 84 | tuafngjrid(lrwlwizrfx) = fkktbqneqg ocsqsrfvoh (btmchhfspr ) View more | Positive | 11 Sep 2025 | ||
tuafngjrid(lrwlwizrfx) = yxcizrastz ocsqsrfvoh (btmchhfspr ) View more | |||||||
Phase 1/2 | Advanced Cervical Carcinoma Second line | 55 | cltythmfgn(bmbhsnarmt) = aaxdymyzph geuzioelge (cskyimrlpy ) View more | Positive | 30 May 2025 | ||
ubuqhnlfir(kvmekmexho) = hwoauqtesj hkykltklrg (ybebbzepjn ) View more | |||||||
Phase 1/2 | Advanced Cervical Carcinoma First line | 41 | tduuttshiq(wfnblboaka) = 1 SAE of bilateral lung pneumonia in the 10 mg/kg group was assessed related to ZG005 by the investigator njvmnisput (yajsdmkgdg ) | Positive | 30 May 2025 | ||
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free